Just after adding a Director to the board in a deal, to avoid his third proxy battle with the company in many years, Billionaire investor Carl Icahn shared that he will push to sell Biogen Idec Inc.

Following many deaths, rheumatoid arthritis and lupus drugs are being pulled off by Swiss pharmaceutical companies Roche and Biogen. After being observed by monitoring board, the two drugs were found to be immensely infectious and even deadly in some cases.

Biogen Idec Inc revealed that patients reporting successful treatment by drug Tysabri increased to 30 percent and sales of its multiple Sclerosis drug crossed $1 billion mark in 2009.